Inactive

Solicitation Number: 75N95024Q00339_SB Title: Cellink BioX6 Gen3 3-D bioprinter and accessories Classification Code: 6640-LABORATORY EQUIPMENT AND SUPPLIES NAICS Code: 541714 - Research and Developmen... Solicitation Number: 75N95024Q00339_SB Title: Cellink BioX6 Gen3 3-D bioprinter and accessories Classification Code: 6640-LABORATORY EQUIPMENT AND SUPPLIES NAICS Code: 541714 - Research and Development in Biotechnology (except Nano biotechnology) Size Standard: 1,000 employees Description: Cellink BioX6 Gen3 3-D bioprinter and accessories (1 Printer + Bioprinter Platform + DNA Software + Remote installation and training) Includes 12-month warranty. This is a Small Business Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding: (1) the availability and capability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition; and (4) availability of domestic sources manufactured in the United States in sufficient and reasonably available commercial quantities and of a satisfactory quality. For equipment/supply requirements, responses must include the place of manufacturing (i.e. address if supply/equipment is a domestic end product and include country of manufacture). For equipment/supply requirements, small businesses must also address the size status of the manufacturer under the applicable NAICS code (i.e. address Non-Manufacturer Rule). Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes. No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only. Background: The National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health, aims to catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. 3-D printing offers a transformative approach to pharmaceutical formulation development, facilitating customization, reducing waste, enabling novel drug delivery systems, and expediting the drug development timeline. The acquisition of a new 3-D bioprinter will position NCATS' at the forefront of advancing the research of 3-D printing in pharmaceuticals. Purpose and Objectives: Cellink BioX6 Gen3 3-D bioprinter and accessories. One year warranty included. Project requirements: Cellink BioX6 Gen3 3-D bioprinter and accessories. One year warranty included. Salient characteristics: Item 1 Bio X6 Gen 3 Printer, 6 pneumatic Printheads, 1 Thermoplastic Printhead, Temperature controlled Printhead, 4 Built in Photocuring modules for general crosslinking, 12 months warranty; Item 2 Bio X6 3 D Bioprinter Platform, 4 Built in Photocuring Modules for general crosslinking; Item 3 DNA Studio 4 software for use with BioX/X6 bioprinter, full access to future 1.x versions of DNA studio 4; Item 4 Remote installation and training INK/BIO and; Item 5 Shipping and handling Bio X6. Quantity: One Anticipated period of performance: 30 days after order is placed. Other important considerations: Cite any other information that is necessary for potential respondents to understand the nature of the potential requirement or proposed acquisition. In case domestic sources are available and capable of fulfilling the Government’s need, and a future solicitation is published, the Government will use evaluation preferences in accordance with FAR 25. Capability statement /information sought. Companies that believe they possess the capabilities to provide the required products or services should submit documentation of their ability to meet each of the project requirements to the Contracting Officer. The capability statement must specifically address each of the project requirements separately. Additionally, the capability statement should include 1) the total number of employees, 2) the professional qualifications of personnel as it relates to the requirements outlined, 3) any contractor GSA Schedule contracts and/or other government-wide acquisition contracts (GWACs) by which all of the requirements may be met, if applicable, and 4) any other information considered relevant to this program. Capability statements must also include the Company Name, Unique Entity ID from SAM.gov, Physical Address, and Point of Contact Information. The response must include the respondents’ technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses. Interested companies are required to identify their type of business, applicable North American Industry Classification System (NAICS) Code, and size standards in accordance with the Small Business Administration. The government requests that no proprietary or confidential business data be submitted in a response to this notice. However, responses that indicate the information therein is proprietary will be properly safeguarded for Government use only. Capability statements must include the name and telephone number of a point of contact having authority and knowledge to discuss responses with Government representatives. Capability statements in response to this market survey that do not provide sufficient information for evaluation will be considered non-responsive. When submitting this information, please reference the solicitation notice number. One (1) copy of the response is required and must be in Microsoft Word or Adobe PDF format using 11-point or 12-point font, 8-1/2” x 11” paper size, with 1” top, bottom, left and right margins, and with single or double spacing. The information submitted must be in and outline format that addresses each of the elements of the project requirement and in the capability statement /information sought paragraphs stated herein. A cover page and an executive summary may be included but is not required. The response is limited to ten (10) page limit. The 10-page limit does not include the cover page, executive summary, or references, if requested. All responses to this notice must be submitted electronically to the Contract Specialist and Contracting Officer. Facsimile responses are NOT accepted. The response must be submitted to Patricia da Silva at the e-mail address patricia.dasilva@nih.gov. The response must be received on or before June 18, 2023, 12:00 pm, Eastern Time. “Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a presolicitation synopsis and solicitation may be published in www.sam.gov. However, responses to this notice will not be considered adequate responses to a solicitation. Confidentiality: No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).”

Inactive

PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. TH... PRE-SOLICITATION NOTICE OF INTENT NON-COMPETITIVE INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA) at the National Insitutes of Health (NIH) on behalf of the National Center for Advancing Translational Sciences (NCATS) intends to negotiate and award a purchase order of Cellink BioX6 Gen3 3-D bioprinter and accessories to: Cellink LLC, 155 Seaport Blvd, Unit 2B, Boston, MA 02210. The essential characteristics of the Cellink BioX6 Gen3 3-D bioprinter and accessories that limit the availability to a sole source is that this purchase is a direct replacement for an existing Celllink bioprinter and must match in form, fit, and function to allow the use of proprietary printer heads that will be retained. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541714 Research and Development in Biotechnology (except Nano biotechnology). Number of Employees: 1000. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) currently in effect at https://www.acquisition.gov/ STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures. DESCRIPTION OF REQUIREMENT Project Description See Attachment 1 – Purchase Description Purpose and Objectives The purpose of this requirement is to procure a Cellink BioX6 Gen3 3-D bioprinter and accessories for NCATS. Period of Performance The anticipated delivery is July 30, 2024. CLOSING STATEMENT This synopsis is not a request for competitive proposals, however, interested parties may submit a capability statement for consideration. Responses to this Notice must include clear and convincing evidence of the offeror’s capability of fulfilling the requirement. In addition the Unique Entity Identifier (UEI), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 12:00 PM EST June 12, 2024. Responses must be emailed to the Contracting Officer at patricia.dasilva@nih.gov and reference the Notice ID 75N95024Q00339.